Apollomics, Inc. (APLM)
Apollomics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Foster City, CA, US. The stock last traded at $17.04, down 6.17% on the session, giving a market capitalisation of $37.4M. On trailing twelve-month figures it carries a trailing P/E of -2.25, a net margin of -128.7%. Its beta of 1.45 implies it has historically moved more than the broad market.
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Apollomics, Inc. is most often compared with the following Healthcare names: